T2 Biosystems, Inc., a company known for its rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has announced that it will release its financial results for the first quarter of 2024 on May 6, 2024, after the market closes. The company will also provide business updates during this time.
Investors who wish to listen to the conference call can access a live and archived webcast of the event at www.t2biosystems.com, specifically on the Investors page in the Events & Presentations section. To participate in the call, dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with the passcode 160751 approximately ten to five minutes before the start time.
T2 Biosystems is committed to improving patient care and reducing healthcare costs by enabling clinicians to treat patients more efficiently. The company’s product lineup includes the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, all of which leverage the proprietary T2 Magnetic Resonance (T2MR) technology. Additionally, T2 Biosystems has a pipeline of upcoming products, such as the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. For more information about T
